West Pharmaceutical Services, Inc.
336.94USD
-0.8100 (-0.24%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 2.9B | 2.9B | 2.9B | 3.1B | 3.4B | 3.6B |
| Q1 | 720.0M | 716.6M | 695.4M | 698.0M | 844.9M | — |
| Q2 | 771.3M | 753.8M | 702.1M | 766.5M | 872.3M | — |
| Q3 | 686.9M | 747.4M | 746.9M | 804.6M | 825.9M | — |
| Q4 | 708.7M* | 732.0M* | 748.8M* | 805.0M* | 827.5M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 7.73 | 7.88 | 6.69 | 6.79 | 8.96 | 9.96 |
| Q1 | 2.29 | 1.85 | 1.55 | 1.23 | 1.92 | — |
| Q2 | 2.48 | 2.06 | 1.51 | 1.82 | 2.15 | — |
| Q3 | 1.59 | 2.14 | 1.85 | 1.92 | 2.19 | — |
| Q4 | 1.36* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| 1.82* |
| 1.77* |
| 1.82* |
| 2.27 |
| — |